{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:27:30Z","timestamp":1773772050114,"version":"3.50.1"},"reference-count":69,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["SJU"],"abstract":"<jats:p>Purpose: In randomised clinical trials, doublet and triplet therapy improved survival compared to standard androgen deprivation therapy (ADT) in men with de novo metastatic castration-sensitive prostate cancer (mCSPC). Guidelines recommend doublet therapy since 2020 and triplet therapy since 2022. The aim of this study was to assess the uptake of upfront doublet and triplet therapy at a population level and assess trends in survival for all men with mCSPC.\nMethods: We included men registered with de novo mCSPC in 2016\u20132024 in the National Prostate Cancer Register of Sweden. We estimated the annual proportion of men with de novo mCSPC who upfront received doublet therapy (ADT plus androgen receptor pathway inhibitor [ARPI] or docetaxel) or triplet therapy (ADT plus docetaxel and ARPI). Kaplan\u2013Meier curves were used to estimate 3-year overall survival.\nResults: In 9294 men diagnosed with de novo mCSPC, the use of upfront doublet therapy increased from 19% in 2016 to 66% in 2024, and the use of triplet therapy rose from 4% in 2021 to 17% in 2024. Uptake was highest among men below age 65 years, of whom 46% received doublet and 48% received triplet therapy in 2024. Three-year survival increased from 51% (95% CI: 49\u201352%) in 2016\u20132018 to 61% (95% CI: 58\u201364%) in 2022\u20132024. Among men below age 65, survival increased from 69% (95% CI: 65\u201373) in 2019\u20132021 to 77% (95% CI: 71\u201384) in 2022\u20132024.\nConclusions: The uptake of doublet and triplet therapy increased substantially during the study period, in particular among men below age 65. In parallel, 3-year overall survival increased in all men diagnosed with de novo mCSPC. These data provide support for the benefit of upfront doublet or triplet therapy in clinical practice.<\/jats:p>","DOI":"10.2340\/sju.v61.45652","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:12:38Z","timestamp":1773760358000},"page":"51-57","source":"Crossref","is-referenced-by-count":0,"title":["Uptake of doublet and triplet therapy for men with de novo metastatic castration-sensitive prostate cancer. Population-based study"],"prefix":"10.2340","volume":"61","author":[{"given":"Paolo","family":"Zaurito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Gedeborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Garmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Ventimiglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats","family":"Alhberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e4r","family":"Stattin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Westerberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"145164","doi-asserted-by":"crossref","unstructured":"Sathianathen NJ, Koschel S, Thangasamy IA, et al. Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Eur Urol. 2020;77(3):365\u2013372.","DOI":"10.1016\/j.eururo.2019.09.004"},{"key":"145165","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2019.09.004","DOI":"10.1016\/j.eururo.2019.09.004"},{"key":"145166","doi-asserted-by":"crossref","unstructured":"James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338\u2013351.","DOI":"10.1056\/NEJMoa1702900"},{"key":"145167","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1702900","DOI":"10.1056\/NEJMoa1702900"},{"key":"145168","doi-asserted-by":"crossref","unstructured":"Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352\u2013360.","DOI":"10.1056\/NEJMoa1704174"},{"key":"145169","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1704174","DOI":"10.1056\/NEJMoa1704174"},{"key":"145170","doi-asserted-by":"crossref","unstructured":"Vale CL, Burdett S, Rydzewska LHM, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016;17(2):243\u2013256.","DOI":"10.1016\/S1470-2045(15)00489-1"},{"key":"145171","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(15)00489-1","DOI":"10.1016\/S1470-2045(15)00489-1"},{"key":"145172","doi-asserted-by":"crossref","unstructured":"Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet. 2022;399(10336):1695\u20131707.","DOI":"10.1016\/S0140-6736(22)00367-1"},{"key":"145173","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(22)00367-1","DOI":"10.1016\/S0140-6736(22)00367-1"},{"key":"145174","doi-asserted-by":"crossref","unstructured":"Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132\u20131142.","DOI":"10.1056\/NEJMoa2119115"},{"key":"145175","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa2119115","DOI":"10.1056\/NEJMoa2119115"},{"key":"145176","doi-asserted-by":"crossref","unstructured":"Jian T, Zhan Y, Hu K, et al. Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Front Pharmacol. 2022;13:955925.","DOI":"10.3389\/fphar.2022.955925"},{"key":"145177","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fphar.2022.955925","DOI":"10.3389\/fphar.2022.955925"},{"key":"145178","unstructured":"Schaeffer EM, Srinivas S, Adra N, et al. NCCN guidelines\u00ae insights: prostate cancer, version 3.2024. J Natl Compr Canc Netw. 2024;22(3):140\u2013150."},{"key":"145179","doi-asserted-by":"crossref","unstructured":"Tilki D, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II \u2013 2024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2024;86(2):164\u2013182.","DOI":"10.1016\/j.eururo.2024.04.010"},{"key":"145180","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2024.04.010","DOI":"10.1016\/j.eururo.2024.04.010"},{"key":"145181","doi-asserted-by":"crossref","unstructured":"Bratt O, Carlsson S, Fransson P, et al. The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease. Scand J Urol. 2022;56(4):278\u2013284.","DOI":"10.1080\/21681805.2022.2093396"},{"key":"145182","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2022.2093396","DOI":"10.1080\/21681805.2022.2093396"},{"key":"145183","doi-asserted-by":"crossref","unstructured":"Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630\u2013642.","DOI":"10.1016\/j.eururo.2016.08.002"},{"key":"145184","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2016.08.002","DOI":"10.1016\/j.eururo.2016.08.002"},{"key":"145185","doi-asserted-by":"crossref","unstructured":"Corsini C, Garmo H, Orrason AW, et al. Survival trend in individuals with de novo metastatic prostate cancer after the introduction of doublet therapy. JAMA Netw Open. 2023;6(10):e2336604.","DOI":"10.1001\/jamanetworkopen.2023.36604"},{"key":"145186","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.36604","DOI":"10.1001\/jamanetworkopen.2023.36604"},{"key":"145187","doi-asserted-by":"crossref","unstructured":"Schoen MW, Doherty J, Eaton D, et al. Treatment patterns and survival among veterans with de novo metastatic hormone-sensitive prostate cancer. JAMA Netw Open. 2025;8(5):e259433.","DOI":"10.1001\/jamanetworkopen.2025.9433"},{"key":"145188","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.9433","DOI":"10.1001\/jamanetworkopen.2025.9433"},{"key":"145189","doi-asserted-by":"crossref","unstructured":"Raval AD, Chen S, Littleton N, et al. Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review. BJU Int. 2025;135(3):408\u2013421.","DOI":"10.1111\/bju.16577"},{"key":"145190","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bju.16577","DOI":"10.1111\/bju.16577"},{"key":"145191","doi-asserted-by":"crossref","unstructured":"Stattin P. How to improve cancer care by use of guidelines and quality registers. Scand J Urol. 2024;59:190\u2013192.","DOI":"10.2340\/sju.v59.42272"},{"key":"145192","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/sju.v59.42272","DOI":"10.2340\/sju.v59.42272"},{"key":"145193","doi-asserted-by":"crossref","unstructured":"Stranne J. 2023\/2024 update of the national prostate cancer guidelines in Sweden. Scand J Urol. 2024;59:210\u2013211.","DOI":"10.2340\/sju.v59.42656"},{"key":"145194","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/sju.v59.42656","DOI":"10.2340\/sju.v59.42656"},{"key":"145195","doi-asserted-by":"crossref","unstructured":"Tomic K, Berglund A, Robinson D, et al. Capture rate and representativity of The National Prostate Cancer Register of Sweden. Acta Oncol. 2015;54(2):158\u2013163.","DOI":"10.3109\/0284186X.2014.939299"},{"key":"145196","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3109\/0284186X.2014.939299","DOI":"10.3109\/0284186X.2014.939299"},{"key":"145197","doi-asserted-by":"crossref","unstructured":"Tomic K, Sandin F, Wigertz A, et al. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer. 2015;51(1):101\u2013111.","DOI":"10.1016\/j.ejca.2014.10.025"},{"key":"145198","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2014.10.025","DOI":"10.1016\/j.ejca.2014.10.025"},{"key":"145199","doi-asserted-by":"crossref","unstructured":"Van Hemelrijck M, Garmo H, Wigertz A, et al. Cohort profile update: The National Prostate Cancer Register of Sweden and prostate cancer data base \u2013 a refined prostate cancer trajectory. Int J Epidemiol. 2016;45(1):73\u201382.","DOI":"10.1093\/ije\/dyv305"},{"key":"145200","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/ije\/dyv305","DOI":"10.1093\/ije\/dyv305"},{"key":"145201","doi-asserted-by":"crossref","unstructured":"Westerberg M, Holm L, Garmo H, et al. Cohort profile update: the National Prostate Cancer Register of Sweden and PCBase. Int J Epidemiol. 2025;54(5):dyaf172.","DOI":"10.1093\/ije\/dyaf172"},{"key":"145202","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/ije\/dyaf172","DOI":"10.1093\/ije\/dyaf172"},{"key":"145203","doi-asserted-by":"crossref","unstructured":"Gedeborg R, Sandin F, Thellenberg-Karlsson C, et al. Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in Sweden. Scand J Urol. 2023;58:9578.","DOI":"10.2340\/sju.v58.9572"},{"key":"145204","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/sju.v58.9572","DOI":"10.2340\/sju.v58.9572"},{"key":"145205","doi-asserted-by":"crossref","unstructured":"Ventimiglia E, Gedeborg R, Orrason AW, et al. A comparison of comorbidity indices and estimates of life expectancy for men with prostate cancer. Scand J Urol. 2025;60:105\u2013107.","DOI":"10.2340\/sju.v60.43810"},{"key":"145206","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/sju.v60.43810","DOI":"10.2340\/sju.v60.43810"},{"key":"145207","doi-asserted-by":"crossref","unstructured":"Westerberg M, Irenaeus S, Garmo H, et al. Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: nationwide, population-based register study. PLoS One. 2024;19(1):e0296804.","DOI":"10.1371\/journal.pone.0296804"},{"key":"145208","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1371\/journal.pone.0296804","DOI":"10.1371\/journal.pone.0296804"},{"key":"145209","doi-asserted-by":"crossref","unstructured":"Westerberg M, Garmo H, Robinson D, et al. Target trial emulation using new comorbidity indices provided risk estimates comparable to a randomized trial. J Clin Epidemiol. 2024;174:111504.","DOI":"10.1016\/j.jclinepi.2024.111504"},{"key":"145210","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jclinepi.2024.111504","DOI":"10.1016\/j.jclinepi.2024.111504"},{"key":"145211","doi-asserted-by":"crossref","unstructured":"Gedeborg R, Sund M, Lambe M, et al. An aggregated comorbidity measure based on history of filled drug prescriptions: development and evaluation in two separate cohorts. Epidemiology. 2021;32(4):607\u2013615.","DOI":"10.1097\/EDE.0000000000001358"},{"key":"145212","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/EDE.0000000000001358","DOI":"10.1097\/EDE.0000000000001358"},{"key":"145213","doi-asserted-by":"crossref","unstructured":"Fallara G, Gedeborg R, Bill-Axelson A, et al. A drug comorbidity index to predict mortality in men with castration resistant prostate cancer. PLoS One. 2021;16(7):e0255239.","DOI":"10.1371\/journal.pone.0255239"},{"key":"145214","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1371\/journal.pone.0255239","DOI":"10.1371\/journal.pone.0255239"},{"key":"145215","doi-asserted-by":"crossref","unstructured":"Gedeborg R, Garmo H, Robinson D, et al. Prescription-based \u00adprediction of baseline mortality risk among older men. PLoS One. 2020;15(10):e0241439.","DOI":"10.1371\/journal.pone.0241439"},{"key":"145216","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1371\/journal.pone.0241439","DOI":"10.1371\/journal.pone.0241439"},{"key":"145217","doi-asserted-by":"crossref","unstructured":"Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343\u2013346.","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"145218","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/0197-2456(96)00075-X","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"145219","doi-asserted-by":"crossref","unstructured":"Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991;9(1):191\u2013192.","DOI":"10.1200\/JCO.1991.9.1.191"},{"key":"145220","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.1991.9.1.191","DOI":"10.1200\/JCO.1991.9.1.191"},{"key":"145221","doi-asserted-by":"crossref","unstructured":"Jackson CH. flexsurv: a platform for parametric survival modeling in R. J Stat Softw. 2016;70:i08.","DOI":"10.18637\/jss.v070.i08"},{"key":"145222","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.18637\/jss.v070.i08","DOI":"10.18637\/jss.v070.i08"},{"key":"145223","doi-asserted-by":"crossref","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.","DOI":"10.1186\/1471-2458-11-450"},{"key":"145224","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/1471-2458-11-450","DOI":"10.1186\/1471-2458-11-450"},{"key":"145225","doi-asserted-by":"crossref","unstructured":"Godtman R, Holmberg E, Stranne J, et al. High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm. Scand J Urol Nephrol. 2011;45(4):226\u2013232.","DOI":"10.3109\/00365599.2011.559950"},{"key":"145226","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3109\/00365599.2011.559950","DOI":"10.3109\/00365599.2011.559950"},{"key":"145227","doi-asserted-by":"crossref","unstructured":"Barlow L, Westergren K, Holmberg L, et al. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48(1):27\u201333.","DOI":"10.1080\/02841860802247664"},{"key":"145228","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/02841860802247664","DOI":"10.1080\/02841860802247664"},{"key":"145229","doi-asserted-by":"crossref","unstructured":"Hussain M, Fizazi K, Shore ND, et al. Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review. JAMA Oncol. 2024;10(6):807\u2013820.","DOI":"10.1001\/jamaoncol.2024.0591"},{"key":"145230","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.0591","DOI":"10.1001\/jamaoncol.2024.0591"},{"key":"145231","doi-asserted-by":"crossref","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u20131216.","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"145232","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7","DOI":"10.1016\/S0140-6736(20)30314-7"}],"container-title":["Scandinavian Journal of Urology"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/45652\/53183","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/45652\/53183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:13:02Z","timestamp":1773760382000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/view\/45652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":69,"URL":"https:\/\/doi.org\/10.2340\/sju.v61.45652","relation":{},"ISSN":["2168-1813"],"issn-type":[{"value":"2168-1813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}